New chemical and radiochemical syntheses are described for the preparation of [F]Rho6G-DEG-F, an F-labeled analogue of the fluoresecent dye rhodamine 6G, which has shown promise as myocardidal perfusion imaging agent. Tosylated precursors of [F]Rho6G-DEG-F amenable to F-labeling were obtained either through a two-step synthesis from rhodamine 6G lactone (33% yield), or in one step from rhodamine 575 (64% yield), then purified by preparative C chromatography. Manual synthesis of [F]Rho6G-DEG-F was achieved in a single radiochemical step from either the tosylate salt or the tosylate/formate double salt in DMSO under standard nucleophillic aliphatic F-fluorination conditions (K[F]F/KCO/Kryptofix 2.2.2.). Incorporation of the [F]F was found to be satisfactory (≥34% by TLC), despite the protic character of the precursor molecules. [F]Rho6G-DEG-F was manually synthesized in final decay-corrected radiochemical yields of 11-26% (tosylate salt) and 9-21% (tosylate/formate double salt). The protocol was transferred to an automated synthesis unit, where the product was obtained in 3-9% radiochemical yield (=3) decay corrected to start-of-synthesis, >99% radiochemical purity, and a molar activity of 122-267 GBq/μmol (3.3-7.2 Ci/μmol).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739059PMC
http://dx.doi.org/10.1039/C7MD00326ADOI Listing

Publication Analysis

Top Keywords

chemical radiochemical
8
perfusion imaging
8
tosylate salt
8
tosylate/formate double
8
double salt
8
[f]rho6g-deg-f
5
radiochemical
5
radiochemical routes
4
routes [f]rho6g-deg-f
4
[f]rho6g-deg-f delocalized
4

Similar Publications

Prostate cancer (PCa) has emerged to be the second leading cause of cancer-related deaths in men. Molecular imaging of PCa using targeted radiopharmaceuticals specifically to PCa cells promises accurate staging of primary disease, detection of localized and metastasized tumours, and helps predict the progression of the disease. Glutamate urea heterodimers have been popularly used as high-affinity small molecules in the binding pockets of popular and well-characterized PCa biomarker, prostate specific membrane antigen (PSMA).

View Article and Find Full Text PDF

Background: Reactive astrogliosis refers to functional and morphological changes in astrocytes that occur with neuronal damage in numerous neurological conditions. PET tracers targeting monoamine oxidase B (MAO-B) are used to visualize reactive astrogliosis in the living brain. [18F]SMBT-1, a MAO-B selective PET tracer, was developed by modifying the chemical structure of [18F]THK5351.

View Article and Find Full Text PDF

"Motion Capture Suit Sign" for Immunotherapy-Induced Inflammatory Arthritis on 99mTc-MDP Bone Scintigraphy.

Clin Nucl Med

February 2025

Division of Chest and Critical Care, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

We report the 99mTc-MDP bone scan of a 44-year-old man with a history of lung adenocarcinoma and recent multiple joint pain after completing pembrolizumab immunotherapy treatment. This interesting image of symmetric uptakes around bilateral joints throughout the skeleton resembles the ball sensors on a motion capture suit. Hence, we recommend naming this distinctive imaging appearance as the "motion capture suit" sign.

View Article and Find Full Text PDF

Prostate cancer ranks as the fourth most common cancer among men, with approximately 1.47 million new cases reported annually. The emergence of prostate-specific membrane antigen (PSMA) as a critical biomarker has revolutionized the diagnosis and treatment of prostate cancer.

View Article and Find Full Text PDF

Current Progress and Future Directions in Non-Alzheimer's Disease Tau PET Tracers.

ACS Chem Neurosci

January 2025

Research Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, Miyagi 980-0845, Japan.

Alzheimer's disease (AD) and non-AD tauopathies are dominant public health issues driven by several factors, especially in the aging population. The discovery of first-generation radiotracers, including [F]FDDNP, [C]PBB3, [F]flortaucipir, and the [F]THK series, for the in vivo detection of tauopathies has marked a significant breakthrough in the fields of neuroscience and radiopharmaceuticals, creating a robust new category of labeled compounds: tau positron emission tomography (PET) tracers. Subsequently, other tau PET tracers with improved binding properties have been developed using various chemical scaffolds to target the three-repeat/four-repeat (3R/4R) tau folds in AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!